The extended suppression of LH produced by the PEG-modified aptamer, and the absent immunogenicity of NOX 1255 and NOX 1257 (in rabbits), makes these aptamers suitable agents for use in research (where GnRH-mediated pathways are being investigated) and as therapeutic agents (such as in assisted fertility cycles where endogenous LH suppression is required and in prostate cancer to produce androgen suppression). This evidence concerns the gene PLOD1 and prostate carcinoma.